---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-001616"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:33:23.841121+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dyadic sells Alphazyme equity interest for ~$1.27M, retains sublicense rights

## Summary
- Received approx. $1.27M from sale of Alphazyme equity interest.
- Non-exclusive sublicense remains; Dyadic gets milestone/royalty payments on C1-expressed products.
- Potential additional payments based on future sales of Alphazyme's existing products.
- Alphazyme Sale Agreement executed January 18, 2023.

## SEC filing metadata
- accession: 0001437749-23-001616
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/0001437749-23-001616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/dyai20230116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-001616
- JSON: https://secwatch.observer/filing/0001437749-23-001616.json
- Plain text: https://secwatch.observer/filing/0001437749-23-001616.txt

## Key facts
- Material Agreements
  DYADIC INTERNATIONAL INC entered into Alphazyme Sale Agreement with Alphazyme, LLC valued at approximately US$1.27 million (effective 2023-01-18).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Alphazyme, LLC
  - Value: approximately US$1.27 million
  - Effective: 2023-01-18
  source text: On January 18, 2023, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into a Securities Purchase Agreement under which the Company agreed to sell its equity interest in Alphazyme, LLC (the "Alphazyme Sale Agreement").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000143774923001616/0001437749-23-001616-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.